With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...
The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn.
Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results